[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6104 followers
Created: 2025-07-23 13:56:25 UTC

Senores Pharma Q1 FY26 Results: XX% PAT Growth & Strategic Expansion Plans 💊📈 | MCap XXXXXXXX Cr

- Profit after Tax (PAT) for Q1 FY26: ₹21 Cr, up XX% YoY.
- Regulated Markets Revenue: ₹90 Cr (69% YoY growth), EBITDA Margin: 35.5%.
- Emerging Markets Revenue: ₹29 Cr (32% YoY growth), EBITDA Margin: 6%.
- Launched X own ANDA products & received approval for X in Regulated Markets.
- Regulated Markets: XX Own commercial products, XX Approved ANDA, XX Pipeline.
- Emerging Markets: XXX Registered products, XXX under Registration in 40+ countries.
- CDMO/CMO segment scaling up with new contracts & increased customer share.
- Positive Operating Cash Flow: ₹11 Cr in Q1 FY26.
- X formulation facilities (US & India), X API facilities (India), strong R&D.
- Targeting pan-India Branded Generics leadership by FY26 end.

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of X pages)

![](https://pbs.twimg.com/media/GwjBJTUbAAAgzxA.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948019372016161201/c:line.svg)

**Related Topics**
[tax bracket](/topic/tax-bracket)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1948019372016161201)